April 2026
1. DEVELTERE D, Tsantoulis P, Olivier T
   Censoring patterns and inconsistent results in checkpoint inhibitor and adjuvant BCG trials for high-risk bladder cancer.
   Eur J Cancer. 2026;240:116740.
   

   >> Share

   
   October 2025
2. STOCKEM CF, van Dorp J, van Dijk N, Vis DJ, et al
   Final clinical analysis of pre-operative ipilimumab and nivolumab in locally advanced urothelial cancer and exploration of tumor-draining lymph node composition: The NABUCCO trial.
   Eur J Cancer. 2025;229:115731.
   

   >> Share

   
   July 2025
3. RIEGER C, Schluchtermann J, Heidenreich J, Steenbock O, et al
   Cost-effectiveness analysis of perioperative durvalumab plus platin-based chemotherapy in muscle invasive bladder cancer in Germany.
   Eur J Cancer. 2025;227:115621.
   

   >> Share

   
   May 2025
4. DUWE G, Mercier D, Kauth V, Moench K, et al
   Development of an artificial intelligence-generated, explainable treatment recommendation system for urothelial carcinoma and renal cell carcinoma to support multidisciplinary cancer conferences.
   Eur J Cancer. 2025;220:115367.
   

   >> Share

   
   October 2024
5. OZBAY MF, Ilhan Y
   Letter Re: High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma.
   Eur J Cancer. 2024;210:114254.
   

   >> Share

   
   August 2024
6. HONG H, Qu Y
   Letter re: High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma.
   Eur J Cancer. 2024;207:114173.
   

   >> Share

   
   April 2023
7. CHUNG R, McKiernan J, Arpaia N, Marabelle A, et al
   Neo-Adjuvant immunotherapies: Bladder cancer as a platform for drug development targeting mucosal immunity.
   Eur J Cancer. 2023;187:58-64.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share